MODULARCMC
LIVE

Serial Number

99256867

Owner

Wheeler Bio, Inc.

Attorney

Ava R. Shelby

First Use Date

Oct 25, 2024

Filing Date

Jun 27, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MODULARCMC Trademark

Serial Number: 99256867

MODULARCMC is a trademark filed by Wheeler Bio, Inc. on June 27, 2025. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Wheeler Bio, Inc. (2 trademarks)

120 Robert S Kerr Ave
Oklahoma City, OK 73102

Entity Type: 03

Trademark Details

Filing Date

June 27, 2025

Registration Date

June 16, 2026

First Use Anywhere

October 25, 2024

First Use in Commerce

October 25, 2024

Goods & Services

Pharmaceutical and biopharmaceutical drug development services; pharmaceutical and biopharmaceutical research and development; development of pharmaceuticals, biopharmaceuticals, pharmaceutical preparations, medicines, pharmaceutical packaging and drug delivery technologies; research and development of new products for others; product development consultation; product research services, namely, providing analytical testing, biosafety testing, reporting and laboratory services for others; scientific and technical consulting and research services in the field of pharmaceuticals; consultation in the field of pharmaceutical drug delivery and dosage technologies; custom design and development of chemical reagents and biochemical assays; Biotechnology research; Chemical research; research and development services in the field of antibodies being antibody technology; biotechnology research and development services for others, namely, mammalian cell line development and therapeutic antibody development; development and analysis services relating to the use of mammalian cell cultures in the field of biotechnology; providing medical and scientific technology research information in the field of pharmaceuticals and biopharmaceuticals, including discovery, preclinical, and clinical drug research and development; toxicological safety testing services for pharmaceuticals and biopharmaceuticals; pharmaceutical contract development in a cGMP (Current Good Manufacturing Practice) compliant facility in the field of pharmaceutical and biopharmaceutical drug development; laboratory testing services in clinical research and clinical trials of innovator medicines in the pharmaceutical and biotechnology fields; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of pharmaceutical and biopharmaceutical drug development; analytical services, namely, providing Good Laboratory Practices (GLP) testing and quality assurance services to assess clinical performance in the field of pharmaceutical and biopharmaceutical drug evaluation and development

Manufacture of pharmaceuticals and biopharmaceuticals to the order and specification of others; biomanufacturing for others, namely, manufacturing of biological products using biological organisms in the manufacturing process for the purpose of facilitating drug development; manufacturing services for others in the fields of mammalian cell line development and therapeutic antibody development; Manufacturing process consulting; contract manufacturing services of biopharmaceuticals, namely, antibodies and recombinant proteins utilizing mammalian cell culture to the order and specification of others; manufacturing services for others in a cGMP (Current Good Manufacturing Practice) compliant facility in the field of pharmaceutical and biopharmaceutical drug development

Business consulting services relating to product distribution, operations management services, logistics, reverse logistics, supply chain, and production systems and distribution solutions; Business management services, namely, managing logistics, reverse logistics, supply chain services, supply chain visibility and synchronization, supply and demand forecasting and product distribution processes for others; business consulting services in the field of commercialization of pharmaceutical products; distributorship services in the field of pharmaceuticals, biopharmaceuticals, health care products and medical products; Invoicing services; Order fulfillment services; customer services in the nature of responding to customer inquiries for others in the field of pharmaceutical product distribution and logistics; inventory control services, namely, computerized business record management of pharmaceutical business data; inventory management in the field of pharmaceuticals and pharmaceutical products; computerized tracking and tracing of packages in transit; electronic customer ordering services for pharmaceuticals, pharmaceutical products, medical products and equipment, laboratory supplies and equipment

Filing History

APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
May 18, 2026 CNTA
USE AMENDMENT ACCEPTED
May 18, 2026 IUAA
AMENDMENT TO USE PROCESSING COMPLETE
May 15, 2026 AUPC
USE AMENDMENT FILED
May 15, 2026 IUAF
TEAS AMENDMENT OF USE RECEIVED
May 15, 2026 EAAU
AMENDMENT TO USE PROCESSING COMPLETE
May 15, 2026 AUPC
USE AMENDMENT FILED
May 15, 2026 IUAF
TEAS AMENDMENT OF USE RECEIVED
May 15, 2026 EAAU
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 15, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 4, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 4, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 18, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 18, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 18, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 17, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 4, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 27, 2025 MAFR
NEW APPLICATION ENTERED
Jun 27, 2025 NWAP